UCB VP named chairman of board at BCI Pharma

6 July 2020

Belgian biotech BCI Pharma has appointed Didier Malherbe (pictured above) as chairman of the board of directors.

Mr Malherbe, managing director of UCB (Euronext: UCB) Belgium and vice president, head of public affairs at the Brussels-based drugmaker, has been brought in to increase the accountability of BCI and pave the way for creating a mature biotech company.

His expertise will enable the company to build and improve its business strategy, extend the BCI network and increase its level of compliance. Mr Malherbe will also be responsible for guiding the company on legal affairs and turning BCI into a more structured company aligned with current pharma expectations.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK